Debate Over Drug Lawsuits Continues
Should individuals be allowed to sue pharmaceutical manufacturers when adverse reactions not clearly identified on drug labels occur? A recent court case has brought that question up for debate again.
The White House and the FDA general counsel say no. Drug regulators and advocacy group leaders say yes. David G. Savage reports on this Oct. 30 story for the Los Angeles Times.
Latest posts by admin aapc (see all)
- US gets the ball rolling on ICD-11 - August 16, 2019
- Message From Your Region 7 Representatives | October 2018 - October 24, 2018
- Message From Your Region 6 Representatives | October 2018 - October 24, 2018